EUVIMEDEUVIMED entdecken
Crossref

Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice

José Manuel Alcalá Ramírez Del Puerto, Isabel Ortega-Madueño, María José Gil-Moreno, Pablo Abizanda-Saro, Marta Palacios-Sarmiento, Rafael Millán-Guirado, María Cruz-Cárdenas, Jordi A Matías-Guiu iD

Journal of Alzheimer’s Disease · 2026-06 · 111 (3) · 979-984

DOI: 10.1177/13872877261438522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 06.04.2026. Verfasst von José Manuel Alcalá Ramírez Del Puerto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology. Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Apolipoprotein E4, Apolipoproteins E. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The apolipoprotein E ε4 allele ( APOE ε4) is associated with higher incidence of amyloid-related imaging abnormalities in patients with Alzheimer's disease undergoing anti-amyloid therapy, underscoring the importance of allele status testing. In this study, plasma ApoE4 levels were measured in 70 participants using Lumipulse ® G Pan-ApoE and ApoE4 assays and compared with traditional genotyping. ApoE4 concentrations and ratio ApoE4/Pan-ApoE differed significantly across non-ε4, ε3/ε4, and ε4/ε4 groups. No correlation was observed with age, sex, creatinine levels, or AD cerebrospinal fluid biomarkers. Diagnostic performance was excellent, indicating that proteotyping of ApoE can accurately classify the main APOE haplotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseApolipoprotein E4Apolipoproteins EHumansFemaleMaleGenotypeAgedAged, 80 and overBiomarkers

Stichwörter der Autor:innen

APOEAlzheimer's diseaseblood-based biomarkersimmunoassayproteotyping

Substanzen

Apolipoprotein E4Apolipoproteins EBiomarkers

Autor:innen und Institutionen

  • Department of Neurology. Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.
  • Department of Clinical Analysis, Institute of Laboratory, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC), Universidad Complutense de Madrid, Madrid, Spain.

ORCID-Profile: Jordi A Matías-Guiu

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Alcalá Ramírez Del Puerto, J. M., Ortega-Madueño, I., Gil-Moreno, M. J., Abizanda-Saro, P., Palacios-Sarmiento, M., Millán-Guirado, R., Cruz-Cárdenas, M., & Matías-Guiu, J. A. (2026). Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice. Journal of Alzheimer’s Disease, 111(3), 979-984. https://doi.org/10.1177/13872877261438522

Vancouver

Alcalá Ramírez Del Puerto JM, Ortega-Madueño I, Gil-Moreno MJ, Abizanda-Saro P, Palacios-Sarmiento M, Millán-Guirado R, et al. Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice. Journal of Alzheimer’s Disease. 2026;111(3):979-984. doi:10.1177/13872877261438522

BibTeX
@article{AlcalRamrezDelPuerto2026,
  author = {Alcalá Ramírez Del Puerto, José Manuel and Ortega-Madueño, Isabel and Gil-Moreno, María José and Abizanda-Saro, Pablo and Palacios-Sarmiento, Marta and Millán-Guirado, Rafael and Cruz-Cárdenas, María and Matías-Guiu, Jordi A},
  title = {Apolipoprotein E proteotyping as a valid alternative to genotyping in clinical practice},
  journal = {Journal of Alzheimer’s Disease},
  year = {2026},
  volume = {111},
  number = {3},
  pages = {979--984},
  doi = {10.1177/13872877261438522}
}
Kostenlos starten →